Radient Pharmaceuticals Corporation fka RXPC

[guardiangel]

This is why we believe ProvistaDX will use Radient shell to go public..imo Wolf

"Since then Provista has brought on an two additional technology for development called the LC Sentinel Test, a blood test for the detection of Ovarian Cancer;"

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=106030255

guardiangel Monday, 09/08/14 12:59:47 AM
Re: dcspka post# 24879
Post # of 26364
DC Ready to get linked in...DC In 2007 William wasn't even interested in Lung Cancer test until he along with Provista Diagnostics connected with Radient/AMDL Inc...Turkey ....Down below is a link you should set your eyes on..Follow the money..The LC Sentinel was Provista's Test for Ovarian..When William Combined LC Sentinel with DR-70...That is when William realized they had a diamond in the rough..The Lung Cancer Test..It stated 2 additional LC Sentinel Tests..One for Ovarian Cancer and the other LC Sentinel for Lung Cancer..imo Wolf

https://tr.linkedin.com/company/provista-diagnostics

Provista Diagnostics sirketinden haberdar olun

********************************************************************

http://www.devicespace.com/news_story.aspx?NewsEntityId=52960


Provista Life Sciences LLC Announces the Opening of Its Clinical Laboratory - Provista Diagnostics (PDx)

4/19/2007 12:57:52 PM

PHOENIX--(BUSINESS WIRE)--Provista Life Sciences LLC (PLS) announced today the opening of its clinical laboratory operations, Provista Diagnostics, LLC (PDx). PDx is a wholly owned subsidiary of PLS. The laboratory will provide the necessary analytical support to advance the clinical trials and commercialization efforts of the first three diagnostic technology companies under PLS’ management umbrella: GW Medical Technologies’ LymPro® Test for the early detection of Alzheimer’ disease, Biomarker Technologies’ BT Test™ for the early detection of breast cancer and RCP Diagnostics’ RCP-Dx Test™ for the detection of women’s estrogen associated cancers: ovarian, uterine, cervical and breast.

“Provista Life Sciences is a biotechnology commercialization organization that identifies and acquires the rights to promising medical diagnostics technologies. We then unify their respective operational and business development activities under our management company,” says PLS CEO William Gartner. “Provista Diagnostics will provide a complementary and critical addition to our diagnostic development strategy supporting the further development of our existing women’s oncology and Alzheimer’s diagnostics. It will also serve as our conduit for early market introduction of these Tests.”

PDx has the exclusive U.S. rights to these tests and plans to introduce these diagnostic services to the public under a direct-to-consumer and health care provider access plan. The test services will provide consumers and their respective health care providers with a means to make earlier and better informed decisions regarding their personal health care needs related to their respective cancer or Alzheimer’s disease.

“We are advancing the development and commercialization of diagnostic technologies that have the potential for early disease state recognition as well as therapeutic drug development and efficacy monitoring,” says Donald Weber, Vice President of Strategic Alliances for PLS. Weber stated that PDx expects to commercially introduce the BT and RCP-Dx Test Services this summer followed by the LymPro Test Service in early 2008.

“These are extremely important blood diagnostics,” says Weber. “Early detection has been recognized as a key component, if not the most important to cancer survival, and to the treatment of Alzheimer’s disease. Our goal is to make sure these test services are available to the public as soon as feasibly possible.”

About Provista Diagnostic LLC

Provista Diagnostics was established in 2007 and is a CLIA registered laboratory focused on the development and commercialization of three breakthrough blood diagnostic for the detection of Breast Cancer, Women’s Estrogen Related Cancers (Ovarian, Uterine, Cervical, and Breast) and Alzheimer’s disease (AD). All three diagnostics will be initially released as adjunctive tests to be used in conjunction with or separate from existing diagnostic procedures such as imaging techniques, PET Scans, etc. Each such diagnostic is intended to assist the individual’s physician or health care provider to better diagnose the respective disease covered by these tests and provide a more accurate and earlier detection of these devastating diseases. For more information, visit the company’s web site at www.ProvistaDx.com or call 602-840-8333 .

Provista Life Sciences’ Background

Provista Life Sciences was established in 2006 as a biotechnology mezzanine development organization that provides the scientific and operating management resources to rapidly advance the development and introduction of novel diagnostics technologies into the domestic and global marketplace. For more information, visit the company’s web site at www.provistals.com or call 602-224-5500 .

Contacts

Provista Life Sciences LLC Andrea Black, 602-224-5500 [e-mail] www.ProvistaLS.com

$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$


Company Description: Provista develops and commercializes, through its own CLIA compliant laboratory, breakthrough diagnostic tests for significant medical illnesses, primarily where no clinical test exists. It was established and incorporated in 2007 as a means of consolidating three separate diagnostic technology companies being operated and managed by Provista Management; i.e. GW Medical Technologies LLC, est. 2004 (LymPro Test), Biomarker Technologies LLC, est. 2004 (BT Test) and RCP Diagnostics LLC, est. 2005 (RCP Test). Since then Provista has brought on an two additional technology for development called the LC Sentinel Test, a blood test for the detection of Ovarian Cancer;

http://www.zoominfo.com/s/#!search/profile/company?companyId=232997250&targetid=profile